BIOGEN INC. Cash and Restricted Cash
BIOGEN INC. (BIIB) had Cash and Restricted Cash of $3.38 billion as of 2026-03-31, per its 10-Q filed 2026-04-29.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-04-29
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $3.38B.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $3.01B.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $3.86B.
- 2025-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $2.76B.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-03-31 | $3.38B 10-Q · filed 2026-04-29 |
| 2025-12-31 | $3.01B 10-Q · filed 2026-04-29 |
| 2025-09-30 | $3.86B 10-Q · filed 2025-10-30 |
| 2025-06-30 | $2.76B 10-Q · filed 2025-07-31 |
| 2025-03-31 | $2.60B 10-Q · filed 2026-04-29 |
| 2024-12-31 | $2.38B 10-Q · filed 2026-04-29 |
| 2024-09-30 | $1.70B 10-Q · filed 2025-10-30 |
| 2024-06-30 | $1.91B 10-Q · filed 2025-07-31 |
| 2024-03-31 | $1.07B 10-Q · filed 2025-05-01 |
| 2023-12-31 | $1.05B 10-K · filed 2026-02-06 |
| 2023-09-30 | $2.29B 10-Q · filed 2024-10-30 |
| 2023-06-30 | $2.62B 10-Q · filed 2024-08-01 |
| 2023-03-31 | $2.90B 10-Q · filed 2024-04-24 |
| 2022-12-31 | $3.42B 10-K · filed 2026-02-06 |
| 2022-09-30 | $3.68B 10-Q · filed 2023-11-08 |
| 2022-06-30 | $2.65B 10-Q · filed 2023-07-25 |
| 2022-03-31 | $1.75B 10-Q · filed 2023-04-25 |
| 2021-12-31 | $2.26B 10-K · filed 2025-02-12 |
| 2021-09-30 | $1.54B 10-Q · filed 2022-10-25 |
| 2021-06-30 | $1.74B 10-Q · filed 2022-07-20 |
| 2021-03-31 | $1.22B 10-Q · filed 2022-05-03 |
| 2020-12-31 | $1.33B 10-K · filed 2024-02-14 |
| 2020-09-30 | $2.22B 10-Q · filed 2021-10-20 |
| 2020-06-30 | $2.38B 10-Q · filed 2021-07-22 |
| 2020-03-31 | $2.59B 10-Q · filed 2021-04-22 |
| 2019-12-31 | $2.91B 10-K · filed 2023-02-15 |
| 2019-09-30 | $2.34B 10-Q · filed 2020-10-21 |
| 2019-06-30 | $1.72B 10-Q · filed 2020-07-22 |
| 2019-03-31 | $2.24B 10-Q · filed 2020-04-23 |
| 2018-12-31 | $1.22B 10-K · filed 2022-02-03 |
| 2017-12-31 | $1.57B 10-K · filed 2021-02-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |